tbuckley/cabot-search huggingface dataset:
Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.
Authors: Peter L Greenberg, Guillermo Garcia-Manero, Michael R Moore, Lloyd E. Damon, Gail J. Roboz, Helen Wei, Hagop Kantarjian, Janet L. Franklin
Journal: Blood (2009)
Feasibility study of neo-chemoradiotherapy for stage IB/II/III esophageal squamous cell carcinoma: A 4-year follow up
Authors: Ken Kato, Takashi Kojima, Yoshinori Ito, Hiroyasu Igaki, Hiroyuki Daiko, Masakatsu Onozawa, Yasuo Hamamoto, Naoyuki Matsushita, Kengo Nagashima, Susumu Katano
Journal: Annals of Oncology (2016)
DRES-16. A CEREBROSPINAL FLUID MICRORNA SIGNATURE FOR ASSESSMENT OF GLIOBLASTOMA TUMOR BURDEN
Authors: Clark Chen, Johnny Akers, Value Ramakrishnan, Ying Mao, Wei Hua, Bob Carter
Journal: Neuro-Oncology (2016)

Clinical care for glioblastoma patients is largely limited by the absence of sensitive biomarkers for assessment of tumor burden or recurrence after therapy. Both clinical examination and MRI are insensitive measures of disease status. For instance, the lowest resolution for reliable detection by MRI is on the order of millimeters. Considering the size of a tumor cell, this limitation in resolution translates into a delay of at least ten cell divisions before therapeutic resistance can be detected. Tumor recurrence is necessarily associated with an increase in the burden of disease. To develop a sensitive biomarker platform that afford assessment of glioblastoma tumor burden, matched clinical glioblastoma specimens and Cerebrospinal fluids (CSF) from the same patient were profiled using the TaqMan OpenArray miRNA platform. CSFs from non-oncology patients were also profiled in parallel. While only ~25% of tumor miRNA are detected in the matched CSF, excellent correlation was noted between the relative abundance of CSF miRNA and tumor miRNA. A nine miRNA signature that discriminated glioblastoma CSF from non-oncology patients was identified. The signatures consistently validated in CSF derived from four independent cohorts summing to 89 glioblastoma patients and 65 non-oncologic patients. For CSF derived from the cerebral ventricle, the sensitivity and specificity for glioblastoma detection were 55-80% and 67-87%, respectively. For CSF derived from lumbar puncture, the sensitivity and specificity for glioblastoma detection were 13-28% and 95-100%, respectively. The study represents the largest miRNA profiling effort of clinical glioblastoma CSF specimens to date with rigorous validation in independent patient cohorts. The results provide evidence supporting CSF miRNA signature as a biomarker platform for detection of glioblastoma recurrence.
The role of the skin microbiome in atopic dermatitis: a systematic review
Authors: R.D. Bjerre, J. Bandier, L. Skov, L. Engstrand, J.D. Johansen
Journal: British Journal of Dermatology (2017)

Dysbiosis is a hallmark of atopic dermatitis (AD). The composition of skin microbiome communities and the causality of dysbiosis in eczema have not been well established. The objective of this review is to describe the skin microbiome profile in AD and address whether there is a causal relationship between dysbiosis and AD. The protocol is registered in PROSPERO (CRD42016035813). We searched PubMed, Embase, Scopus and ClinicalTrials.gov for primary research studies applying culture‐independent analysis on the microbiome on AD skin of humans and animal models. Two authors independently screened the full text of studies for eligibility and assessed risk of bias. Because of heterogeneity no quantitative synthesis was done. Of 5735 texts, 32 met the inclusion criteria (17 published: 11 human and six animal studies). The studies varied in quality and applied different methodology. The skin in AD had low bacterial diversity (lowest at dermatitis‐involved sites) and three studies showed depletion of Malassezia spp. and high non‐Malassezia fungal diversity. The relative abundance of Staphylococcus aureus and Staphylococcus epidermidis were elevated and other genera were reduced, including Propionibacterium. A mouse study indicated that dysbiosis is a driving factor in eczema pathogenesis. The data are not sufficiently robust for good characterization; however, dysbiosis in AD not only implicates Staphylococcus spp., but also microbes such as Propionibacterium and Malassezia. A causal role of dysbiosis in eczema in mice should encourage future studies to investigate if this also applies to humans. Other important aspects are temporal dynamics and the influence of methodology on microbiome data.
MPTH-40. COPY NUMBER ALTERATIONS IN PLEOMORPHIC XANTHOASTROCYTOMA AND ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA: CHARACTERIZATION OF 40 CASES BY SNP ARRAY
Authors: Rachael Vaubel, Alissa Caron, Paul Decker, Seiji Yamada, Jeanette Eckel-Passow, Fausto Rodriguez, Amulya NageswaraRao, Daniel Lachance, Ian Parney, Robert Jenkins, Caterina Giannini
Journal: Neuro-Oncology (2016)

Pleomorphic xanthoastrocytoma (PXA), a rare localized brain tumor morphologically and genetically distinct from infiltrating astrocytoma, shows frequent BRAF V600E mutation, frequent loss of CDKN2A/B and lacks IDH1/2 mutation. To further characterize its underlying genetic alterations, we performed OncoScan SNP array in 40 PXAs: 26 PXA (WHO grade II) and 14 anaplastic (A-PXA) (WHO grade III). BRAF V600E mutation was present in 24 (60%) cases: 17 PXA (65%) and 7 A-PXA (50%). Homozygous CDKN2A/B deletion, the most frequent alteration (n=34,85%) together with other chromosome 9 alterations [including copy neutral loss of heterozygosity (cnLOH), loss, and gain], was present in an equal proportion of PXA (81%) and A-PXA (92%) and of BRAF V600E mutant (83%) and wildtype (88%) tumors. In 5 PXAs, chromosome 9 alterations were present in isolation. Whole chromosome gains/losses were frequent, including gains +7 (n=13), +5 (9), +20 (8), +21 (8), +2 (8), +12 (7), +15 (6) and losses -22 (14), -14 (8), -13 (6). Losses were significantly more common in A-PXA, including -22 (p=0.001), -14 (p=0.015), and -13 (p<0.001). Whole chromosome/whole arm cnLOH was identified in 14 cases, most commonly involving chromosome 9 (n=8). High level 8p and 12q amplification was identified in a single tumor. Five matched PXA and recurrent A-PXA were compared. Upon anaplastic transformation, two tumors demonstrated nearly identical copy number alterations (CNAs), two cases showed additional complex CNAs, and one case showed additional loss of -18q and partial -11q. Distinct areas of low- and high-grade morphology were analyzed in two tumors; one showed identical CNAs and one numerous additional complex CNAs. Overall, CDKN2A/B homozygous deletion is identified in the vast majority of PXA regardless of grade and BRAF mutation status and persists on recurrence/anaplastic transformation. The presence of BRAF mutation and CDKN2A/B loss may help to differentiate A-PXA from glioblastoma in morphologically challenging cases.
Accuracy of Immunofluorescence in the Diagnosis of Primary Ciliary Dyskinesia
Authors: Amelia Shoemark, Emily Frost, Mellisa Dixon, Sarah Ollosson, Kate Kilpin, Mitali Patel, Juliet Scully, Andrew V. Rogers, Hannah M. Mitchison, Andrew Bush, Claire Hogg
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: The standard approach to diagnosis of primary ciliary dyskinesia (PCD) in the United Kingdom consists of assessing ciliary function by high-speed microscopy and ultrastructure by election microscopy, but equipment and expertise is not widely available internationally. The identification of biallelic disease-causing mutations is also diagnostic, but many disease-causing genes are unknown, and testing is not widely available outside the United States. Fluorescent antibodies to ciliary proteins are used to validate research genetic studies, but diagnostic utility in this disease has not been systematically evaluated.Objectives: To determine utility of a panel of six fluorescent labeled antibodies as a diagnostic tool for PCD.Methods: The study used immunofluorescent labeling of nasal brushings from a discovery cohort of 35 patients diagnosed with PCD by ciliary ultrastructure, and a diagnostic accuracy cohort of 386 patients referred with symptoms suggestive of disease. The results were compared with diagnostic outcome.Measurements and Main Results: Immunofluorescence correctly identified mislocalized or absent staining in 100% of the discovery cohort. In the diagnostic cohort immunofluorescence successfully identified 22 of 25 patients with PCD and normal staining in all 252 in whom PCD was considered highly unlikely. In addition, immunofluorescence provided a result in 55% (39) of cases that were previously inconclusive. Immunofluorescence results were available within 14 days, costing $187 per sample compared with electron microscopy (27 days; cost $1,452).Conclusions: Immunofluorescence is a highly specific diagnostic test for PCD, and it improves the speed and availability of diagnostic testing. However, sensitivity is limited and immunofluorescence is not suitable as a stand-alone test.
Real-world survival results of metastatic melanoma patients treated with ipilimumab in the Netherlands
Authors: A. Jochems, M. Schouwenburg, M. Aarts, F. van den Berkmortel, A. van den Eertwegh, G. Groenewegen, J.-W. de Groot, J.B.A.G. Haanen, G. Hospers, E. Kapiteijn, R. Koornstra, W. Kruit, B. Leeneman, M. Louwman, D. Piersma, R. van Rijn, A.J. Ten Tije, G. Vreugdenhil, M. Wouters, J. van der Hoeven
Journal: Annals of Oncology (2016)
TGF-beta regulates CD44 expression of cancer cells through epithelial-to-mesenchymal transition in malignant ascites
Authors: Michitaka Nakano, Mamoru Tanaka, Risa Tanaka, Akitaka Makiyama, Keita Uchino, Taito Esaki, Kenji Mitsuki, Eishi Baba
Journal: Annals of Oncology (2016)
Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.
Authors: Anne Novak, Takashi Akasaka, Michelle Manske, Mamta Gupta, Thomas Witzig, Martin JS Dyer, Ahmet Dogan, Ellen Remstein, Stephen Ansell
Journal: Blood (2008)
Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece
Authors: A. Solakidi, G. Kourlaba, L. Kontovinis, E. Bournakis, A. Boutis, K. Koutsoukos, J. Syrios, A. Tzovaras, M. Chatzikou, C. Michailidi, N. Maniadakis
Journal: Annals of Oncology (2016)
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.
Authors: Ash A Alizadeh, Andrew J Gentles, Alvaro J. Alencar, Holbrook E Kohrt, Roch Houot, Neha Talreja, Ragini Shyam, Yasodha Natkunam, Randy D. Gascoyne, Javier Briones, Ranjana Advani, Izidore S Lossos, Ronald Levy
Journal: Blood (2009)
Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma
Authors: T. Ebata, T. Shimoi, S. Bun, M. Yunokawa, K. Yonemori, T. Ishiwata, S. Iwasawa, K. Tamura, Y. Takiguchi
Journal: Annals of Oncology (2016)
An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)
Authors: Y.-J. Bang, L.W. Goff, H. Wasserstrom, J. Yang, G. Mi, M. Karasarides, M. Reck
Journal: Annals of Oncology (2016)
PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study
Authors: R. Graf, D. Lu, R. Krupa, J. Louw, L. Dugan, A. Jendrisak, S. Orr, K. Bethel, Y. Wang, M. Suraneni, M. Landers, D. Boffa, J. Nieva, L. Bazhenova, M. Salazar, S. Makani, M. Magana, R. Dittamore
Journal: Annals of Oncology (2016)
Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma
Authors: Markus Brockmann, Evon Poon, Teeara Berry, Anne Carstensen, Hedwig E. Deubzer, Lukas Rycak, Yann Jamin, Khin Thway, Simon P. Robinson, Frederik Roels, Olaf Witt, Matthias Fischer, Louis Chesler, Martin Eilers
Journal: Cancer Cell (2016)
P11.06 Expression of somatostatin receptors in meningiomas: Correlation of molecular PET-imaging and in-situ expression
Authors: S. Iglseder
Journal: Neuro-Oncology (2016)

AbstractSomatostatin receptors (SSTR) are expressed in the majority of meningiomas and represent the basis for somatostatin-analogue positron emission tomography (PET) such as 68Ga-DOTATOC. The high expression of SSTR in meningioma cells not only serves as a target for diagnosis, but also enables the development of specifically targeted therapy approaches. Therefore, the aim of this retrospective study was to confirm the correlation between 68Ga-DOTATOC-PET/CT and the expression intensity of the SSTR in surgically removed meningioma tissue evaluated by immunohistochemical analysis.Material and Methods:We identified 18 surgical specimens generated from histologically confirmed meningioma patients who underwent preoperative 68Ga-DOTATOC-PET/CT. Semi-quantitative assessment of tissue receptor expression of 6 different SSTR subtypes (SSTR1,2A,2B,3,4,5) was performed using the immunoreactive-score (IRS). 68Ga-DOTATOC-PET/CT scans were quantified, the maximal standard uptake value (SUVmax) was measured and the tumor-to-pituitary (SUVmax-T/P) as well as the tumor-to background-uptake ratios (SUVmax-T/B) were calculated.Results:All 18 tumor specimens were SSTR positive on immunohistochemistry. Tumor-specific 68Ga-DOTATOC uptake was detected in all patients with a median SUVmax of 12.3 (range 1.3–44.9). The IRS for SSTR2A, SSTR2B and SSTR5 correlated highly significant with the SUVmax on PET (p<0.001; p=0.001; p=0.012). SUVmax-T/P and SUVmax-T/B were correlated with SSTR2A reaching highly statistical significance (p=0.002; p<0.001).Conclusion:The highly significant correlation between SSTR2A and SUVmax as well as SUVmax-T/P and SUVmax-T/B on 68Ga-DOTATOC-PET/CT scans proofs somatostatin analogues as a valuable tool in the diagnosis of meningiomas. Furthermore, the significant correlation between SSTR imaging using 68Ga-DOTATOC-PET/CT with immunohistochemically analyzed SSTR expression provides SSTR as a potential target for meningioma specific therapy in patients not amenable to standard treatment modalities.
Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)
Authors: Jeffrey A Silverman, Walter E. Aulitzky, John Lister, Lori Maness, Gary J Schiller, Karen Seiter, Scott Smith, Wendy Stock, Dina Ben Yehuda, Steven R. Deitcher
Journal: Blood (2010)
PDCT-15. Re-MATCH: A PHASE 2 MULTI-INSTITUTIONAL CLINICAL TRIAL OF ADOPTIVE CELLULAR THERAPY FOLLOWING MYELOABLATIVE OR NON-MYELOABLATIVE CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Authors: Sridharan Gururangan, Elias Sayour, Brian Cleaver, Nathalie Clement, David Pincus, William Slayton, John Fort, Paul Castillo, Marcia Hodik, Renee Boyette, Nina McGrew, Jennifer King, Jianping Huang, Changlin Yang, Anjelika Dechkovskaia, Jeffrey Drake, Duane Mitchell
Journal: Neuro-Oncology (2016)

Patients with relapsed or progressive medulloblastoma and PNETs (reMB/PNETs) who have failed definitive radiotherapy have a dismal prognosis and no effective salvage treatment regimens. We explored whether adoptive cellular therapy (ACT) following standard myeloablative or nonmyeloablative salvage treatment regimens was feasible, safe, and of potential clinical benefit in children and young adults with reMB/PNETs. Pediatric patients and young adults (up to age 30) scheduled for surgical resection or biopsy of first reMB/PNET after having failed definitive cranial radiation therapy +/- spinal radiation were eligible for enrollment. Amplified tumor RNA-pulsed DCs were used to expand tumor-specific lymphocytes ex vivo by co-culture with autologous lymphocytes and IL-2 within our cGMP facility. Patients were enrolled onto one of two treatment arms based on disease staging and eligibility criteria: Group A received induction chemotherapy followed by high-dose chemotherapy and hematopoietic stem cell (HDC+HSC) rescue prior to ACT. Group B received salvage chemotherapy followed by non-meyloablative lymphodepletion with cyclophosphamide and fludarabine followed by ACT. 20 subjects with reMB/PNET have been enrolled on the Re-MATCH protocol. 11 subjects have received ACT, 4 are pending treatment, and 5 were screen failures. There have been no immunotherapy related dose-limiting toxicities. One subject with disseminated (Stage M4) medulloblastoma characterized by leptomeningeal disease, thoracic bony metastasis, and extensive bone marrow infiltration, demonstrated a profound and near complete radiographic and clinical response to treatment. TCR RNA sequencing of peripheral blood lymphocytes has revealed massive clonal expansion of T cells following ACT in this subject. Clinical follow-up is ongoing for primary endpoint analysis of 12-month progression free survival. Adoptive cellular therapy employing amplified total tumor RNA-pulsed DCs as a platform for expanding tumor-specific lymphocytes is feasible, safe, and potentially effective in patients with recurrent/progressive central PNETs. This study has now progressed to a multi-site investigational phase.
TMOD-01. FUNCTIONAL KINOME CHARACTERIZATION OF A DIVERSE PANEL OF GLIOBLASTOMA MODELS
Authors: Robert McNeill, Timothy Stuhlmiller, Ryan Bash, Simon Khagi, Gary Johnson, C. Ryan Miller
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most common malignant primary brain tumor. Treatments are limited and clinical efficacy of kinase inhibitors has been disappointing. The molecular heterogeneity of GBM is well characterized, but knowledge of the GBM kinome is limited. To this end, we utilized a chemical proteomics method consisting of multiplex inhibitor beads and mass spectrometry (MIB-MS) to assess the functional state of tumor kinomes en masse, both in the presence (dynamic profiling) and absence (baseline profiling) of kinase inhibitors. Baseline kinome profiling of patient derived xenografts, established cell lines (ECL), isogenic mutant immortalized human astrocytes (NHA), non-germline genetically-engineered mouse (nGEM) astrocytes, and human GBM demonstrated extensive heterogeneity. Two major subtypes were apparent in human tumors with differential functional expression of RTK (PDGFRβ, IGF1R, MET, EGFR) and their MAPK (ERK1/2 and BRAF) and PI3K (AKT1-3, MTOR) effector arms. We therefore tested the efficacy of MAPK and PI3K inhibition using brain penetrant inhibitors of MEK (selumetinib) and PI3K (buparlisib), in ECL (U251, U87, and LN229), NHA with and without constitutively active mutants in HRAS ± AKT, and nGEM astrocytes harboring homozygous deletion of Trp53 and Nf1 (Trp53;Nf1Del) or T121, KrasG12D and Pten deletion (TRP). Selumetinib IC50 ranged from 2–23 µM, while buparlisib IC50 ranged from 0.7–1.8 µM in all four model systems in vitro. Dynamic profiling of buparlisib treated TRP astrocytes showed broad kinome changes including PI3K inhibition and MAPK activation. Immunoblots confirmed treatment with buparlisib or selumetinib inhibited the targeted pathway and induced alternate activation of the converse arm of RTK signaling. Moreover, we found that dual treatment with buparlisib + selumetinib was synergistic in U87, Trp53;Nf1Del, and TRP astrocytes. Thus, functional kinome analysis using targeted kinase inhibitors and MIB-MS will help define the kinase networks required for GBM pathogenesis and may aid in the identification of novel treatments.
GENT-16. REDEFINING THE CELLULAR ARCHITECTURE OF ADULT AND PEDIATRIC GLIOBLASTOMAS THROUGH LARGE-SCALE SINGLE-CELL ANALYSES
Authors: Mariella Filbin, Itay Tirosh, Cyril Neftel, Volker Hovestadt, Andrew Venteicher, Christine Hebert, McKenzie Shaw, Leah Escalante, Kristine Pelton, Liliana Goumnerova, Thomas Czech, Irene Slavc, Michelle Monje, Pratiti Bandopadhayay, Brian Nahed, Will Curry, Daniel Cahill, David Louis, Keith Ligon, Todd Golub, Aviv Regev, Mario Suva
Journal: Neuro-Oncology (2016)

While human tumors are shaped by the genetic evolution of cancer cells, evidence also suggests that they display superimposed hierarchies reminiscent of normal development. Yet, relating the genetic and hierarchical models of cancer organization has been limited by technical challenges. Here, studying hemispheric and midline pediatric and adult glioblastomas, we profiled thousands of single cells from fresh tumors by RNA-seq and reconstructed the genetic and epigenetic cellular architecture of tumors in patients. We identified that most cancer cells are differentiated along specialized glial programs, while a subpopulation of cells are undifferentiated and associated with neural stem cell expression programs. By identifying distinct genetic clones, we show that these cellular architectures evolve during the progression of the tumors, suggesting that developmental programs and genetic influences coordinately determine tumor architecture. These results provide unprecedented insight into the cellular composition of brain tumors at single-cell resolution and may help harmonize the cancer stem cell and the genetic models of cancer, with critical implications for disease management.
Phase III study of gemcitabine plus vinorelbine (VG) versus vinorelbine (V) in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracyclines (A) and taxanes (T). Final results of GEICAM 2000–04 study
Authors: M. Muñoz, M. Martín, A. Ruiz, A. Balil, J. García-Mata, L. Calvo, C. Jara, E. Alba, F. Salas, C. Soto
Journal: Journal of Clinical Oncology (2006)

575 Background: VG has shown to be efficacious and safe in MBC in pts previously treated with AT. This study compared treatment (TT) V with the combination of VG. Primary objective was progression free survival (PFS). Methods: pts previously treated with AT, aged ≥18, ECOG ≤ 2, were randomized to V: 30 mg/m 2 day (d) 1, d8, or VG 30/1200 mg/m 2 d1, d8, both every 21 days until disease progression. Stratification criteria were previous lines of TT for MBC (0 vs.1 vs.2) and visceral disease (yes vs. no). 126 pts per arm were needed to demonstrate a prolongation in PFS of 2 months (m) (from 3 to 5; HR = 1.67; α and β errors 0.05 and 10). Results: 252 pts (127 V and 125 VG) were recruited between 2001 and 2005. Arms were well balanced: median age was 57 years; median number of metastatic sites 2; visceral disease was present in 75% of pts; 17%, 53% and 29% of pts received study TT as first, second and third line respectively. Median number of cycles were 4 (1–21) in V and 6 (1–26) in VG. Median PFS was 6.3 m (95% CI, 5.3–7.3) for VG and 4.1 m (95% CI, 3.3–4.9) for V (p=0.0011). Objective response rate was 37% (CI 95% 29–46) for VG and 25% (CI 95%: 17–33) for V (p= 0.035). CTC grade 3–4 hematologic toxicity was significantly higher with VG vs. V (65% vs. 43% neutropenia, 33% vs. 17% leucopenia, and 11% vs. 2% thrombocytopenia); febrile neutropenia was present in 10.5% of pts on VG and 6% of pts in V (p=ns). Non-hematological toxicity was low and manageable in both arms. Conclusions: VG demonstrated significant efficacy advantages over V in pts with MBC previously treated with AT, with manageable toxicity. This favorable risk-benefit profile supports the use of this combination in this patient population. [Table: see text]
Correlation of metabolic information on 18F-FDG PET with the tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) candidate to upfront surgery
Authors: L. Toschi, E. Lopci, F. Marchesi, F. Grizzi, D. Rahal, L. Olivari, G. Castino, S. Marchetti, N. Cortese, D. Qehajaj, D. Pistillo, M. Alloisio, M. Roncalli, P. Allavena, A. Santoro, A. Chiti
Journal: Annals of Oncology (2016)